The eEF2 pathway is involved in neurological processes and diseases such as Alzheimer’s disease, where it was found that amyloid-β oligomers activate eEF2K, leading to decreased synaptic plasticity [14, 15], or in depression and epilepsy, where eEF2K inhibition is related to anti-depressant [16–18] and antiepileptic [19] activity. Here, EEF2K is linked to depressive disorder.